Immunotoxin therapy is a promising molecular cancer treatment strategy. Its main advantage is seletive cytotoxicity towards tumor cells and minimal toxicity in normal tissues. However, a short half-life and rapid clearance severely hampers its clinical application. We report here a novel genetic approach in which a recombinant adenovirus vector was used to deliver an immunotoxin gene e23(scFv)-PE40 targeted to the oncogene c-erbB-2 (also known as Her2/neu). This vector, when combined with a low dose of a conditionally replicative adenovirus vector (CRAd), has enhanced tumor-killing ability either alone or in combination with the chemotherapeutic agent etoposide. Our data show that low-dose CRAd facilitated the replication of replication-deficient Ade23(scFv)-PE40 up to 6-20 times and the transcription of e23(scFv)-PE40 gene up to 12 times. Moreover, etoposide increased the e23(scFv)-PE40 transcription up to 8.5 times. Furthermore, we show that systemic application of Ad-e23(scFv)-PE40 and enhanced expression of the immunotoxin gene was well tolerated as determined by serum biochemical markers and histological examination of most vital organs. Taken together, our data support a novel genetic immunotoxin delivery approach that may yield enhanced efficacy against a variety of Her2/neu-expressing tumors.
Introduction
Tumor cells often express unique receptors or antigens that distinguish them from the surrounding normal tissues. These unique antigens/receptors are excellent targets for therapeutics development. One such target is the c-erbB-2 protein, also known as Her-2/neu, which is a 185 kDa glycoprotein (p185) and belongs to the epidermal growth factor transmembrane receptor tyrosine kinase family. This family has at least four members that is, epidermal growth factor receptor (EGFR) (c-erbB-1), c-erbB-2 (Her2/neu), c-erbB-3 and c-erbB-4. Like EGFR, c-erbB-2 protein plays an important role in many physiological processes, such as cell growth, differentiation and tissue development. Its expression was found to be 10-to 100-fold higher in certain tumors, such as the breast, [1] [2] [3] lung, 4 ,5 ovaries, 6, 7 stomach, 8 bladder 9 and pancreas cancers, 10 and has been implicated in the carcinogenesis of these malignancies. Overexpression of c-erbB-2 has also been found to be associated with metastasis and poor prognosis. 11, 12 In contrast, the normal tissue distribution of the c-erbB-2 protein is quite restricted. 13 These characteristics have encouraged a variety of different approaches to develop therapies targeting c-erbB-2 overexpressed tumors. An example of this is a humanized form of anti-c-erbB-2 antibody, trastuzumab (Herceptin; Genentech, San Francisco, CA), which can specifically bind with the extracellular portion of c-erbB-2 and block EGF signal pathway and suppresses tumor growth. Therefore, trastuzumab has become an important therapeutic option for patients with c-erbB-2 overexpressing breast cancer. [14] [15] [16] Another promising approach to target c-erbB-2 is the immunotoxin approach. Immunotoxins are theoretically superior to antibodies alone because they have increased efficacy in killing of c-erbB-2 overexpressing tumor cells. Immunotoxins are composed of the targeting moiety of a monoclonal antibody fused with a bacterial toxin. In preclinical studies with immunotoxins, tumor-specific targeting and selective cytotoxicity were reported. 17, 18 However, results from a phase I clinical trail 19 were less than ideal. In this trial, an immunotoxin consisted of a monoclonal antibody specific for the Lewis Y -related carbohydrate antigen (expressed on multiple carcinomas) fused with Pseudomonus exotoxin A (PEA) were used to treat 46 patients with Lewis Y -positive metastatic carcinomas. Results showed that despite 31% of the patients had stable disease, no complete or partial tumor responses were observed in the 8-week evaluation period. Pharmacokinetic studies showed the half-life t(1/2) of 2.5 ± 0.3 h after intravenous injection of purified immunotoxin at a dosage of 0.641 mg m -2 . Pharmacodynamic analyses also showed a rapid clearance of antibodies by day 11. This is also associated with an antitoxin antibody response in most patients. The short half-life and the rapid onset of antibody response were considered as the main causes for reduced efficacy of immunotoxin therapy. To avoid these shortcomings, many approaches have been tested to maximize the potential for clinical efficacy. One example of an accelerated administration schedule that increases the duration and amount of drug exposure before host development of neutralizing antibodies have being explored. [19] [20] [21] [22] Efforts were also made to produce immunotoxins in mammalian cells so that they will have proper post-translational modifications that may potentially reduce their immunogenicity in human patients.
Another promising strategy to deliver immunotoxin therapy is through gene therapy vectors. The advantages of gene therapy vectors are that they can mediate continuous and prolonged immunotoxin production. In addition, because the immunotoxins are produced locally, there is potentially less issues of host immune reactions. Here, we report a novel approach of adenovirus-mediated gene therapy delivery of immunotoxins. Our approach involves the combined usage of a conditionally replicative adenovirus (CRAd), with a replication-deficient immunotoxin-encoding virus, which showed considerably enhanced gene expression efficacy. In addition, we also found that low doses of chemotherapeutic agents were able to enhance Ad-mediated immunotoxin gene expression.
Materials and methods

Cell lines and culture conditions
Human breast cancer cell line SK-BR-3 and gastric carcinoma cell line SGC-7901 were kindly provided by Dr An`gang Yang (The Fourth Military Medical University, Xı`an, China). Human hepatocarcinoma cell line, SMMC-7721, lung cancer cell line, A549, and human fetal fibroblasts of lung (HFL) were obtained from the cell bank at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. The adenovirus packaging cell line (Ad293) was purchased from Stratagene (La Jolla, CA). All cells were cultured in Dulbecco's modified Eagle's medium or RPMI1640 supplemented with 10% FBS and antibiotics (Invitrogen, Carlsbad, CA).
Construction, package and preparation of adenovirus
The immunotoxin expression cassette, e23(scFv)-PE40, which encodes a single chain antibody against c-erb-B2 fused to a 40 kDa recombinant form of Pseudomonus exotoxin A (PE40), was digested from plasmid pLNCXe23(scFv)-PE40 (kindly provided by Dr Siyi Chen 23, 24 ) and inserted into AdMax shuttle vector pDC316 (Microbix, Toronto, Ontario, Canada) to generate Ad shuttle vector pDC316-e23(scFv)-PE40. Subsequently, Ad-e23(scFv)-PE40 was packaged in Ad293 cells by homologous recombination between pDC316-e23(scFv)-PE40 and plasmid pBHGloxDE1.3cre containing the adenoviral genome. Both plasmids were transfected into Ad293 cells by the use of Lipofectamine 2000 (Invitrogen). Ad-enhanced green fluorescent protein (EGFP) (an E1 deleted replication-deficient adenovirus with EGFP expression cassette), Ad-null (an E1 deleted replicationdeficient adenovirus without any exogenous gene), Ad-TERT-E1A/E1B (a replication-competent adenovirus with telomerase reverse transcriptase promoter-driven E1A/E1B expression cassette) 25 and dl309 (an adenoviral mutant with intact E1) were made or maintained earlier in our laboratory.
To obtain homogeneous population of high-titer recombinant adenovirus vectors, each adenoviral vector was subjected to three rounds of plaque purification, then propagated on Ad293 cells and purified by use of the Adeno-X Virus Purification Kit according to manufacturer's instructions (Becton Dickinson, Palo Alto, CA). Functional titers of all adenoviral vectors were determined by plaque assay on Ad293 cells. The presence of replicative-competent adenovirus was determined by infection and cytopathic assays on A549 cells. PE40 expression in infected cells was determined by western blot analysis.
Western blotting analysis
Cells were lysed and total protein concentration was determined using the Bradford method. About 60 mg of each sample was subjected to electrophoresis on SDS-10% polyacrylamide gels and then transferred to nitrocellulose membrane. Monoclonal anti-erbB-2 (1:1000 diluted, Neomarkers, Freemont, CA), rabbit polyclonal anti-PEA (1:200 diluted, Sigma, St Louis, MO) and monoclonal anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:5000 diluted, Kangchen, Shanghai, China) antibody and appropriate secondary antibodies conjugated with horseradish peroxidase were used. Immunoreactive bands were visualized by Lumi-light western blotting substrate (Roche, Mannheim, Germany).
Cytotoxicity assay in vitro
For cytotoxicity assay in vitro, we applied either recombinant Ad-e23(scFv)-PE40 virus vectors or media harvested from Ad-e23(scFv)-PE40 infected cells to target tumor cell. For cytotoxicity mediated by Ad-e23(scFv)-PE40, 1 Â 10 4 cells per well were plated into 96-well plates with growth medium. After 24 h, Ad-e23(scFv)-PE40 or Ad-EGFP at 0.16, 0.63, 2.5, 10 and 40 multiplicity of infection (MOI) were applied and incubated for another 72 h. Cell viabilities were assessed using MTS/PMS (MTS, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; PMS, phenazine methosulfate) assay kits following instructions of the manufacturer (Promega, Madison, WI). Relative survival rate was calculated using uninfected cells as the control (for example, with its survival rate defined as 1), and CC 50 values were determined as the viral dose that killed 50% of the tested cells.
For cytotoxicity induced by conditioned media harvested from SK-BR-3 tumor cells infected with either 10 MOI Ad-e23(scFv)-PE40 or Ad-EGFP, conditioned medium were collected at 48 h after infection and then mixed with fresh growth medium at different ratios and applied to SK-BR-3 or SGC-7901 tumor cells. Cell viabilities were then evaluated as described above. Each experimental datum point was derived from four replicate wells and each experiment was repeated at least three times. For CRAd or chemotherapeutic agent additive effect observation, 1 Â 10 5 cells per well were plated into 24-well plates and then different MOI of Ad-e23(scFv)-PE40 or Ad-EGFP with or without CRAd or chemotherapeutic agent were added to cells. Later at 72 h after viral infection or chemotherapeutic agent treatment, cell viability was visualized and quantified by the use of crystal violet staining.
Immunostaining of immunotoxin molecule
Immunofluorescent staining was carried out for visualizing the localization of e23(scFv)-PE40 molecule. Briefly, SK-BR-3 or A549 tumor cells were cultured on coverslides in 24-well plates with growth medium and then treated with Ad-e23(scFv)-PE40 at 1.25 MOI or conditioned medium for 48 h. After fixing with 4% paraformaldehyde, slides were incubated with anti-PEA antibody (1:200, Sigma) at 371C for 2 h, followed by tetramethylrhodamine B isothiocyanate (TRITC)-conjugated Swine secondary antibody (1:20, DAKO, Glostrup, Denmark) incubation for 30 min at room temperature. The stained slides were then observed by use of epi-fluorescent microscope. 8 pfu Ad-e23(scFv)-PE40 or Ad-null in 100 ml phosphate-buffered saline (PBS) or 100 ml PBS alone. Four days later, the tumors were removed, fixed in 5% glacial acetic acid-formalin solution, and then embedded in paraffin. The tumor sections were subjected to TUNEL assay and observed by use of an epi-fluorescent microscope. As the antibody was FITC-conjugated, green fluorescent cells observed with epi-fluorescent microscope represented apoptotic cells (Carl Zeiss, Go¨ttingen, Germany).
Quantitative real-time PCR Two separate sets of quantitative real-time PCR experiments were carried out. To detect gene transcription levels, about 5 Â 10 5 SGC-7901 tumor cells were plated into 6-well plates, 24 h later the cells were infected either with 10 MOI Ad-EGFP plus 2 MOI CRAd, or 40 mg ml -1 of VP16 for another 24 h, 48 h or 72 h. A different infection scheme, that is, 6 MOI Ad-e23(scFv)-PE40 with or without 1.2 MOI CRAd or 40 mg ml -1 of VP16 for 24 h, 48 h or 72 h, was also used in some experiments. Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. RNA concentration was determined by spectrophotmetry (Ultrspec3000, Amersham Pharmacia Biotech, Freiburg, Germany). RNA was reverse transcribed with random hexamers using Superscript Firststrand synthesis kit (Invitrogen), then the secondary strand was synthesized according to the manufacturer's instructions. The primers for amplifying EGFP were 5 0 -AGAAGAACGGCATCAAGGTG-3 0 and 5 0 -GAACTC CAGCAGGACCATGT-3 0 , for e23(scFv)-PE40 were 5 0 -CAAGGGCAAGGCCACATT-3 0 and 5 0 -GGCGATGA CGGGTGAAAGT-3 0 , for GAPDH, commonly used reference gene as an internal control, were 5 0 -GAAGGT GAAGGTCGGAGT-3 0 and 5 0 -GAAGATGGTG ATGG GATTTC-3 0 . For quantitative real-time PCR, SYBR Green system was used. In detail, 20 ml of the PCR mixture contains 0.1 ml of cDNA from the reverse transcription, 0.5 mM each of primer, and 10 ml of the reagent from Platinum SYBR Green qPCR SuperMix UDG kit (Invitrogen) and H 2 O. The quantitative PCR reaction were carried out in DNA Engine Opticon 2 (MJ Research, Waltham, MA) with an initial denaturation at 951C for 2 min, then followed by 40 cycles of 10 s of denaturing at 941C, 30 s of annealing at 551C and 30 s of extension at 721C, and ended with 5 min at 721C polymerization. The genomic DNA was also extracted from the infected SGC-7901 tumor cells using Universal Genomic DNA Extraction kit (Takara, Dalian, China), then subjected to be amplified for EGFP, e23(scFv)-PE40 and GAPDH by quantitative PCR as described above. The data were analyzed using the comparative delta-delta cycle threshold (2
ÀDDCt
) model, where DDCt means (C T,EGFP/e23(scFv)ÀPE40 -C T,GAPDH ) sample / (C T,EGFP/e23(scFv)ÀPE40 -C T,GAPDH ) control . 26, 27 The mRNA , the animals were randomly divided into three groups (n ¼ 8), Ad-e23(scFv)-PE40, Ad-EGFP and PBS. About 5 Â 10 8 pfu Ad-e23(scFv)-PE40 or Ad-EGFP in 100 ml of PBS or 100 ml of PBS alone were administered intratumorally every other day for three times. For combined CRAd and replicationdeficient immunotoxin adenovirus treatment, the animals were randomly divided into four groups (n ¼ 8), Ade23(scFv)-PE40, CRAd, Ad-e23(scFv)-PE40 plus CRAd and PBS when tumors grew over 120 mm 3 . About 5 Â 10 8 pfu Ad-e23(scFv)-PE40 or 1 Â 10 8 pfu CRAd, or 5 Â 10 8 pfu Ad-e23(scFv)-PE40 plus 1 Â 10 8 pfu CRAd in 100 ml of PBS or 100 ml of PBS alone were administered intratumorally every other day for three times. Tumor growth was monitored by periodic measurements with calipers, and the tumor volume was calculated using the following formula: (maximal length) Â (perpendicular width) 2 /2. Animals with tumors larger than 1.5 cm in diameter were euthanized. The survival time was then calculated.
Safety and toxicity assay after systemic application of Ad-e23(scFv)-PE40 Balb/c nude mice at 6 weeks old were injected a total of 5 Â 10 8 pfu Ad-e23(scFv)-PE40 in 100 ml of PBS through the tail vein. Then Ad injected mice were randomly divided into four groups (n ¼ 6) and non-injected mice were grouped as control. Animals were sedated with pentobarital sodium, serum samples were collected at 0.25, 1, 3 and 7 days after Ad injection, respectively. Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase, urea, creatinine (CR) and creatine kinase (CK) were measured by Roche modular PP instrument (Roche Diagnostics, Germany) according to procedures provided by the manufacturer. In addition, vital organs such as liver, lung, kidney and heart were collected and processed for conventional histopathologic examination to evaluate potential tissue damage caused by systemic diffusion of Ad-e23(scFv)-PE40 or immunotoxin e23(scFv)-PE40.
Statistical analysis
All numerical data were expressed as mean ± s.d.. A comparison of means among two or more groups was performed using one-way analysis of variance or nonparametric test, and further confirmed by post-hoc analyses with S-N-K or Games-Howell test. All statistical analyses were conducted using SPSS 11.5 software (SPSS, Chicago, IL). Differences with Po0.05 were considered as significant.
Results
Differential c-erbB-2 expression levels among tumor cell lines Western blotting showed that c-erbB-2 expression was dramatically different among tumor cell lines. C-erbB-2 expression was highest in SK-BR-3 cell line, followed in order by SGC-7901, SMMC-7721 and A549. The HFL showed no c-erbB-2 expression at all ( Figure 1A ).
Cytotoxic effect of Ad-e23(scFv)-PE40 and conditioned media from Ad-e23(scFv)-PE40 infected cells Adenoviral vectors were confirmed to be able to infect tumor cells and mediate transgene expression by western blotting ( Figure 1B) . In order to determine the cytotoxic activities of Ad-e23(scFv)-PE40, the infectious efficiency among different tumor cells by serotype 5 adenoviral vector, which was commonly used vectors in gene therapy clinical trails and also in this study, was determined by Ad-EGFP infection and EGFP-positive rate analysis. To do this, SK-BR-3, SGC-7901, SMMC-7721, A549 and HFL cells were infected with 0.63, 2.5, 10 and 40 MOI Ad-EGFP for 72 h, and then analyzed by flow cytometry. The result is shown in Figure 1C and all tested cell lines showed relatively effective infection despite some variations. SMMC-7721 had the highest infection rate (68.8±3.39%), followed in order by SGC-7901 (58.6 ± 2.83%), HFL (42.1 ± 2.22%), SK-BR-3 (38.1 ± 1.98%) and A549 (35.4 ± 1.77%), respectively.
MTS assay was carried out to measure cell viability after Ad-e23(scFv)-PE40 or Ad-EGFP infection. As shown in Figure 1D , SK-BR-3, SGC-7901 and SMMC-7721 cells treated with Ad-e23(scFv)-PE40 showed dosedependent cell killing effects over a 72 h period (Po0.001), whereas A549 and HLF cells showed no significant cell death. SK-BR-3 and SGC-7901 cells were more sensitive to Ad-e23(scFv)-PE40 treatment with viability decreasing to 10.5 ± 4.3% and 15 ± 5.5% at MOI of 40, respectively. The cytotoxic effect was closely associated with c-erbB-2 expression levels in tumor cells because cell lines with lower or no c-erbB-2 expression (as measured by western blotting), showed lower or no cytotoxic effects despite high infection efficiency ( Figure 1C ). The viability of A549 and HFL cells was over 95% at all doses used for infection in this study despite the fact that at least 35% of the A549 and 42% of the HFL cells should be infected. The estimated 50% cytotoxic dose of Ad-e23(scFv)-PE40 to SK-BR-3 and SGC-7901 cells was about 5.51 MOI and 7.06 MOI, respectively. The c-erbB-2 associated cytotoxic effects of Ad-e23(scFv)-PE40 was further confirmed by results from Ad-EGFP infection, which showed over 95% viability at all doses tested ( Figure 1E ).
Medium from Ad-e23(scFv)-PE40 infected SK-BR-3 tumor cells was harvested and mixed with normal growth medium at different ratios and then applied to SK-BR-3 and SGC-7901 cells grown on 96-well plates. The results showed that 1/50 (v/v, conditioned medium/normal growth medium) or higher ratios of mixed media showed cytotoxic effects on SK-BR-3 and SGC-7901. These results suggested that Ad-e23(scFv)-PE40 infection could result in active secretion of immunotoxin molecule e23(scFv)-PE40, which leads to bystander cytotoxic effect (Supplementary Figure S1) .
Evidence of e23(scFv)-PE40 binding with c-erbB-2 positive tumor cell surface To ensure that e23(scFv)-PE40 could indeed be retargeted to c-erbB-2, we used immuno-fluorescence staining with an antibody against PE40 to stain for cells infected with Ad-e23(scFv)-PE40. Our results ( Figure 1F ) clearly showed that fluorescence intensity was correlated with c-erbB-2 expression on tumor cell surface. Strong staining was observed on SK-BR-3 tumor cells (which have high cerbB-2 expression), whereas little was observed on A549 cells (which have low c-erbB-2 expression). These results clearly indicated that the e23(scFv)-PE40 molecule was able to retarget to c-erbB-2 positive cells, which constituted the base of the tumor-specific killing effects.
Ad-e23(scFv)-PE40 killed tumor cells through apoptosis
To characterize the cytotoxic effect of e23(scFv)-PE40, we monitored apoptosis induced by therapeutic adenoviral vector Ad-e23(scFv)-PE40 and control vector Ad-null. The amount of apoptosis, stained by Annexin V-FITC and SYTOX green dye, were quantified by flow Novel strategies to augment immunotoxin effects X Liu et al cytometry and the results showed that apoptosis rates were associated with Ad-e23(scFv)-PE40 in a dosedependent manner but not with Ad-null infection. For example, the apoptotic rate of SK-BR-3 cells infected by Ad-e23(scFv)-PE40 was 6.59 ± 0.66% at 2 MOI then increased to 21.15 ± 1.9% at 20 MOI (Figure 2A ). In comparison, apoptotic rate of SK-BR-3 infected by Adnull showed no obvious change at all MOI tested. DNA fragmentation, a relatively late event of apoptosis, was also evaluated in infected cells by TUNEL assay. As shown in Figure 2B , Figure 2C ). These data suggested that apoptosis was a key mechanism responsible for Ad-e23(scFv)-PE40-mediated tumor cell killing.
Enhanced anti-tumor effect in vitro by combination of CRAd and Ad-e23(scFv)-PE40 As replication-defective adenoviral vectors showed relatively lower efficiency to transfer tumor cells in vivo because of the limited spread and infection in solid tumor, to enhance Ad-e23(scFv)-PE40-mediated tumor cell killing effect, we tested a new strategy where we combined CRAd with Ad-e23(scFv)-PE40 to induce Ad-e23(scFv)-PE40 replication in tumor cell also. The CRAd we used contained a telomerase reverse transcriptase gene promoter-driven E1A/E1B expression cassette so that it could selectively replicate in tumor cells because it is known that more than 90% human tumors have reactivated telomerase reverse transcriptase activities, whereas the vast majority of normal cells do not have telomerase activity. We expected that E1A/E1B, produced by CRAd during infection and replication, could facilitate Ad-e23(scFv)-PE40 replication in trans. The results from in vitro study showed that indeed the combination of Ad-e23(scFv)-PE40 at 12 MOI and CRAd at 1.2 MOI induced more potent oncolysis, which compared with the effect of Ad-e23(scFv)-PE40 alone at 24 MOI (Figure 3) . The enhancing effect of CRAd was correlated with the amount of CRAd used. We further used Ad-EGFP to verify CRAd induced replication-deficient adenovirus replication in tumor cells; we found that both the fraction of EGFP-positive cells and EGFP fluorescence intensity in infected cells were significantly increased ( Figure 4A ). In fact, the viral titers of Ad-EGFP could be increased by as much as 2-20 times with the help of different amount of CRAd ( Figure 4B ). EGFP DNA copy number and EGFP mRNA expression level were analyzed by quantitative PCR and RT-PCR measurements, respectively; about 7.84-fold increase of EGFP DNA copy number and 12.11-fold increase of EGFP mRNA were obtained after 10 MOI Ad-EGFP plus 2 MOI CRAd infection for 72 h (Po0.001, Figure 4C ). The increased EGFP protein expression was observed by western blotting ( Figure 4E ). CRAd-enhanced Ad-e23(scFv)-PE40 replication and expression was also examined, about 6.06-fold increment of e23(scFv)-PE40 DNA copy number and 12.13-fold increment of e23(scFv)-PE40 mRNA were observed when cells were infected with 6 MOI Ad-e23(scFv)-PE40 and 1.2 MOI CRAd for 72 h (Po0.001, Figure 4D ). Increased e23(scFv)-PE40 protein expression was confirmed by western blotting ( Figure 4F ).
Chemotherapeutic agent etoposide (VP16) enhanced anti-tumor effect of Ad-e23(scFv)-PE40
Chemotherapy is the most common used anti-tumor modality for late-stage cancer patients. We therefore tested whether a combination of the chemotherapeutic agent VP16 and Ad-e23(scFv)-PE40 could enhance the anti-tumor effect. As shown in Figure 3 , a single infection with Ad-e23(scFv)-PE40 at 12 MOI or VP16 at 40 mg ml -1 alone showed only minimal or no growth suppression to tumor cells. However, a combination of Ad-e23(scFv)-PE40 at 12 MOI and VP16 at 40 mg ml -1 induced a rapid and complete tumor cell lysis. In addition, this additive anti-tumor effect of VP16 plus Ad-e23(scFv)-PE40 was cerbB-2 expression specific, as SK-BR-3, SGC-7901 and SMMC-7721 cells (with higher c-erbB-2 expression) showed higher amount of oncolytic effects than A549 cells (with lower c-erbB-2 expression). Further tests showed that VP16 at 40 mg ml -1 alone did not induce apparent apoptosis.
To probe the mechanism involved in VP16-mediated cytotoxic effects of Ad-e23(scFv)-PE40, we used Ad-EGFP to examine whether VP16 induced adenovirusmediated transgene expression in tumor cells. We found that the intensity of EGFP fluorescence in infected cells was significantly increased ( Figure 4A ). We further discover that VP16 was able to induce increased expression of EGFP mRNA and protein with no increase in EGFP DNA copy number was observed ( Figure 4C and E). Similar results was also observed in combination of VP16 and Ad-e23(scFv)-PE40 ( Figure 4D and F) . These results suggested that the mechanisms involved in CRAd or VP16 induced transgene expression mediated by replication deficient adenovirus were different.
Anti-tumor effect of Ad-e23(scFv)-PE40 in vivo Given the selective and potent cytotoxic effect of Ad-e23(scFv)-PE40 on c-erbB-2 expression tumor cells in vitro, we subsequently evaluated the effect of Ad-e23(scFv)-PE40 on tumors grown in vivo. As subcutaneous injections of 5 Â 10 6 SK-BR-3 tumor cells failed to develop xenograft tumors, we used the SGC-7901 xenograft tumors for testing anti-tumor effect of Ad-e23(scFv)-PE40. Once the SGC-7901 tumors reached about 40 mm 3 , the animals were randomly divided into three groups (n ¼ 8), and about 5 Â 10 8 pfu Ad-e23(scFv)-PE40 or Ad-EGFP in 100 ml of PBS or 100 ml of PBS alone were administered intratumorally every other day for three times. As seen in Figure 5a , tumors treated with intratumoral injection of Ad-e23(scFv)-PE40 showed significant growth delay than those injected with Ad-EGFP or PBS (Po0.001). Twenty-four days later the average tumor volume in Ad-e23(scFv)-PE40 treated group was 0.24 ± 0.11 cm ). The survival rate of mice, treated with intratumoral injection of Ad-e23(scFv)-PE40, increased significantly than mice treated with Ad-EGFP or PBS (Figure 5b) . These results provided strong proof for the in vivo anti-tumor efficacy of adenovirusmediated e23(scFv)-PE40 expression.
Although intratumoral injection of Ad-e23(scFv)-PE40 significantly delayed growth of SGC-7901 xenograft tumors, this anti-tumor effect was still limited. If tumors were bigger than 100 mm 3 in volume, Ad-e23(scFv)-PE40 failed to suppressed tumor growth effectively. We suspect that low efficacy in bigger tumors is probably caused by the inability to infect a sufficient amount of cells; therefore, we tested a new strategy where we combined CRAd with Ad-e23(scFv)-PE40 to treat the big tumors. Safety and tolerance tests for Ad-e23(scFv)-PE40 in mice As viral leakage can occur after intratumoral injection of adenoviral vector (supplementary Figure S2 ) and may cause damage to liver, we systemically injected 5 Â 10 8 pfu Ad-e23(scFv)-PE40, then collected blood samples and harvested vital organs from host mice at different time points. As shown in Figure 6 , except CK, neither serum biomarkers (ALT, ALP, AST, urea and CR) nor morphologic changes of liver or kidney were observed 7 Novel strategies to augment immunotoxin effects X Liu et al days later. Although serum CK significantly decreased (Po0.001), no obvious histopathologic alterations were observed in the cardiovascular system. Taken together, our results suggest that the use of Ad-e23(scFv)-PE40 is safe and well tolerated by mouse hosts.
Discussion
Despite the two decades of research, the practical application of gene therapy still faces some hurdles. Two significant hurdles are the lack of appropriate therapeutic genes and lower gene transfer efficiency. The ideal therapeutic gene for cancer treatment should be potent and tumor cell-specific. Immunotoxin e23(scFv)-PE40 molecule is a fusion protein, which is composed of a single-chain antibody e23 with high-affinity binding to the extracellular domain of c-erbB-2 and a truncated Pseudomonus exotoxin (PE40) containing translocation and catalytic subunit. [28] [29] [30] PE toxin acts through the ADPribosylation of elongation factor-2 (EF-2) in the cytosol. It destroys target cells by two different mechanisms that is, inhibition of protein synthesis and induction of apoptosis. 31 In Ad-e23(scFv)-PE40 infected cells, PE toxin was produced and secreted by virtue of a signal sequence that leads to the recruitment of newly synthesized toxins into the lumen of the endoplasmic reticulum (ER). 32, 33 Toxin-expressing cells remain viable because interaction of the toxins with EF-2 is blocked by the bi-layer membrane of the ER and secretory vesicles. Secreted toxins selectively target c-erbB-2 expressing cells and destroy target cells only after being internalized and released into the cytosol. Therefore, immunotoxin e23(scFv)-PE40 is tumor cell-specific and has potent cytotoxic effects and bystander effect.
Among the currently available gene transfer vectors, adenovirus has high gene transfer efficiency and broader tropism. As demonstrated in this study, replicationdefective adenovirus-mediated immunotoxin e23(scFv)-PE40 gene transfer led to significant tumor growth Novel strategies to augment immunotoxin effects X Liu et al suppression. Another significant advantage of gene therapy is that therapeutic transgene product is produced in situ, and it has been reported that the replicationdefective adenovirus-mediated transgene expression could last more than 7 days after a single administration of either systemic or intratumoral injection. 34, 35 As majority 8 pfu Ad-e23(scFv)-PE40 each in 100 ml phosphate-buffered saline through the tail vein. At 0.25, 1, 3 and 7 days after injection, six mice were killed and serum and tissues were collected. Serum biomarkers that reflect liver function (Alanine aminotransferase, alkaline phosphatase), kidney function (urea, creatinine), tissue damage (AST) and myocardial damage (creatine kinase (CK)) were analyzed. Serum and tissues collected from non-injected normal mice (n ¼ 6) were used as control. Only CK at 1, 3 and 7 days and CR at 1 day showed significant difference (* indicates Po0.05).
of the therapeutic genes for cancer gene therapy are cytotoxic and harmful to normal cells, the intratumoral application of adenoviral vectors has been wildly accepted. 36 In the case of our adenovirus encoding immunotoxin e23(scFv)-PE40, we examined serum biomarkers and morphology of vital organs after systemic administration. Our data suggested that it could be well tolerated even at Ad-e23(scFv)-PE40 doses given intratumorally.
Conditionally replicative-competent adenovirus, which contains E1A and E1B genes driven by tumor-specific gene promoters, can selectively replicate and lyse tumor cells. The released adenoviral particles can then infect neighboring tumor cells and result in spread of infection. In this study, we combined CRAd with replicationdefective adenovirus carrying the therapeutic gene. We show that CRAd could provide E1 protein in trans to support Ad-e23(scFv)-PE40 replicating in tumor cells and increase the overall transduction efficiency. An advantage of this approach is flexibility to combine two different vectors with increased therapeutics gene-carrying capacity and increased replication efficiency.
Another approach explored in this study is using a low dose of chemotherapeutic agent to augment anti-tumor effect mediated by Ad. Recently etoposide had been reported to enhance adenoviral vector infection efficiency through up-regulating coxsackie-adenovirus receptor expression. [37] [38] [39] As etoposide is widely used in the clinical settings, we explored here the feasibility to use low-dose etoposide to enhance anti-tumor effect of gene therapy mediated by adenoviral vectors and their underlying mechanisms. Our data suggested that etoposide synergistically enhanced adenoviral anti-tumor effect through transcriptional activation of adenoviral vector-mediated therapeutic gene.
Taken together, our combined gene delivery strategy significantly improved transduction efficiency and therapeutic efficacy of immunotoxin therapy in vitro and in vivo in various tumor models.
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